Clinical trial · Interventional
Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Focal therapy (FT) is a new approach to treating localized prostate cancer. Instead of treating the entire prostate, it targets only the cancerous areas while preserving healthy tissue. This helps reduce side effects like urinary, sexual, and bowel problems. In a prospective observational expansion of a phase II clinical trial (ProAMFocal), 80% of patients with small, localized prostate cancers treated with FT had no cancer recurrence at one year, and 70% at 3 years after treatment. The investigators studied the genetic makeup of each cancer, and found that certain genetic markers and cancer subtypes were better at predicting recurrence than standard clinical measures. Based on this, the investigators are launching the FLAME-PC trial. In this study, all patients who qualify for FT will first undergo genetic profiling of their cancer. Patients with favorable profiles (low risk based on genetic markers) will receive FT, while those with high-risk profiles will be advised to undergo standard treatments like prostate removal or radiation. The investigators current main goal is to test if genetic profiling can help us better select patients for FT. They believe that patients chosen using this method will have low recurrence rates (\<10%) compared to those in their previous study (20-30%). FLAME-PC aims to show that personalized treatment based on genetic profiling can improve outcomes for prostate cancer patients, offering effective cancer control with fewer side effects.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Molecular Evaluation for Risk of Recurrence after FT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Focal Therapy, Low Transcriptomic Risk Cohort
- description
- Low Transcriptomic Risk for recurrence after FT: Decipher GC Score \<0.5; OR GC 0.5-0.85 and non PSC-LP subtype
- interventionNames
- Diagnostic Test: Molecular Evaluation for Risk of Recurrence after FT
- type
- EXPERIMENTAL
- label
- Radical Therapy, High Transcriptomic Risk Cohort
- description
- High Transcriptomic Risk for recurrence after FT: Decipher GC 0.5-0.85 and PSC-LP subtype, or GC \>0.85
- interventionNames
- Diagnostic Test: Molecular Evaluation for Risk of Recurrence after FT
- type
- NO_INTERVENTION
- label
- Focal Therapy, Unselected for Transcriptomic Risk of Recurrence (Historical)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Prostate Adenocarcinoma * Grade Group 2-4 * MRI lesion size ≤3ml for single lesions ≤1.5ml for 2 lesions * no gross EPE * assessed to be completely ablatable with margin with focal therapy. Exclusion Criteria: * Grade Group 5 cancer * gross EPE * multifocal (\>2) clinically significant prostate cancer * unablatable location (very apical, basal tumors, or otherwise determined by procedurist).
References
Publications (1)
- BACKGROUNDTay KJ, Hong BH, Ong EHW, Tan KM, Pacho GC, Wong SJ, Tan YG, Law YM, Ngo NT, Tan PH, Yuen JSP, Ho HSS, Chen K, Peng J, Foo CWT, Sam XX, Tuan JKL, Kanesvaran R, Gupta RT, Rozen S, Polascik TJ, Liu Y, Proudfoot J, Davicioni E, Khor LY, Chua MLK. Transcriptomic predictors of prostate cancer recurrence following focal cryotherapy: a pooled analysis of phase II trial and prospective cohort data. J Natl Cancer Cent. 2025 May 29;5(5):515-523. doi: 10.1016/j.jncc.2025.04.002. eCollection 2025 Oct. PMID 41111925